Peel Hunt Keeps Renewi Plc (LON:RWI) as “Buy”; Vbi Vaccines – Ordinary Shares (VBIV) Shorts Down By 1.67%

VBI Vaccines Inc. (NASDAQ:VBIV) Logo

Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV) had a decrease of 1.67% in short interest. VBIV’s SI was 707,300 shares in May as released by FINRA. Its down 1.67% from 719,300 shares previously. With 121,800 avg volume, 6 days are for Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV)’s short sellers to cover VBIV’s short positions. The SI to Vbi Vaccines Inc – Ordinary Shares’s float is 1.84%. The stock increased 5.85% or $0.19 during the last trading session, reaching $3.44. About 435,883 shares traded or 189.30% up from the average. VBI Vaccines Inc. (NASDAQ:VBIV) has declined 30.77% since May 17, 2017 and is downtrending. It has underperformed by 42.32% the S&P500.

In a research report sent to investors on 17 May, Renewi Plc (LON:RWI) stock had its “Buy” Rating restate by investment analysts at Peel Hunt.

Among 3 analysts covering Renewi Plc (LON:RWI), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Renewi Plc has GBX 124 highest and GBX 88 lowest target. GBX 105.33’s average target is 50.47% above currents GBX 70 stock price. Renewi Plc had 16 analyst reports since May 18, 2017 according to SRatingsIntel. The firm earned “Outperform” rating on Thursday, May 18 by Credit Suisse. The stock of Renewi plc (LON:RWI) has “Buy” rating given on Tuesday, January 23 by Peel Hunt. The firm has “Buy” rating given on Thursday, November 9 by Peel Hunt. The rating was maintained by Credit Suisse on Wednesday, July 19 with “Outperform”. The stock of Renewi plc (LON:RWI) has “Buy” rating given on Monday, February 12 by Peel Hunt. The stock has “Buy” rating by Peel Hunt on Wednesday, September 27. The stock of Renewi plc (LON:RWI) earned “Buy” rating by Peel Hunt on Thursday, May 25. The firm has “Neutral” rating given on Tuesday, October 24 by Credit Suisse. As per Friday, September 29, the company rating was maintained by Peel Hunt. Peel Hunt maintained it with “Buy” rating and GBX 118 target in Thursday, March 29 report.

The stock increased 1.16% or GBX 0.8 during the last trading session, reaching GBX 70. About 71,968 shares traded. Renewi plc (LON:RWI) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Renewi plc provides waste-to-product services in the Netherlands, Belgium, the United Kingdom, Germany, France, Portugal, Canada, Hungary, and Luxembourg. The company has market cap of 560.09 million GBP. The firm operates through Commercial Waste, Hazardous Waste, Municipal, and Van Gansewinkel Groep divisions. It currently has negative earnings. It is involved in the collection and treatment of commercial waste; industrial cleaning and treatment of hazardous waste; and operation of waste management facilities under long-term municipal contracts, as well as waste recycling activities.

Among 5 analysts covering VBI Vaccines (NASDAQ:VBIV), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. VBI Vaccines has $11.0 highest and $6 lowest target. $8.50’s average target is 147.09% above currents $3.44 stock price. VBI Vaccines had 7 analyst reports since July 26, 2016 according to SRatingsIntel. As per Wednesday, November 1, the company rating was initiated by Canaccord Genuity. The firm has “Buy” rating given on Wednesday, November 15 by BMO Capital Markets. The firm has “Buy” rating given on Tuesday, July 26 by Ladenburg Thalmann. Laidlaw initiated the stock with “Buy” rating in Monday, October 10 report.

More recent VBI Vaccines Inc. (NASDAQ:VBIV) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” on May 09, 2018. Also Nasdaq.com published the news titled: “VBI Vaccines Announces First Quarter 2018 Financial Results and Provides Corporate Update” on May 01, 2018. Nasdaq.com‘s news article titled: “VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B …” with publication date: April 19, 2018 was also an interesting one.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company has market cap of $220.90 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. It currently has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.

VBI Vaccines Inc. (NASDAQ:VBIV) Ratings Chart